Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren’s disease Cash and investment balance of $491.5 million as of March 31, 2026 expected to provide runway into early 2029 BOSTON, May 13, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “We had another quarter of solid execution for our two global Phase 3 programs in generalized myasthenia gravis and primary Sjögren’s disease, both of which are progressing as planned,” said Jean-Paul Kress, M.D., Chief Executive...

Lite Strategy Continues to Deliver Recurring Yield on Litecoin Holdings and Advance Share Repurchase Program SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) — Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the fiscal 2026 third quarter ended March 31, 2026. Business and Financial Highlights:Active Treasury Management: Successfully continued the Company’s covered call option program, generating $0.7 million in net proceeds since October 2025 and further demonstrating Lite Strategy’s ability to transform its LTC holdings into a yield-generating reserve asset and differentiate itself from passive investment vehicles. Share Repurchase Program: Deployed covered call proceeds and 35,250...

CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY‑813 preclinical data on June 8, 2026 On track to advance CNTY‑308, Century’s CD19‑targeted CAR‑iT cell therapy, into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results...

BROOKFIELD, Conn., May 13, 2026 (GLOBE NEWSWIRE) — Photronics, Inc. (Nasdaq: PLAB), a worldwide leader in photomask technologies and solutions, is scheduled to announce financial results for the second quarter of fiscal 2026 on Thursday, May 28, 2026, before the market opens. Photronics will host a public conference call the same day at 8:30 a.m. Eastern time. During the call, company management will respond to questions concerning, but not limited to, the company’s financial performance, business conditions, and industry outlook. Some responses may contain information not previously disclosed. The call will be broadcast live and on-demand on the Events and Presentations link on the Photronics website. Analysts and investors who wish to participate in the Q&A portion of the call should click here: Conference Registration....

BALLERUP, Denmark, May 13, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the first quarter of 2026. Recent Financial HighlightsQ1 2026 revenue of $4.1 million compared to $4.6 million in Q1 2025. Q1 2026 net loss of $(2.7) million compared to $(2.4) million in Q1 2025. Q1 2026 Adjusted EBITDA of $(1.5) million compared to $(1.4) million in Q1 2025. Ending cash balance of $2.7 million on March 31, 2026.OutlookThe Company is reiterating its expectation for FY 2026 revenue between $23 million and $27 million, which would represent an increase of 39% to 64% over FY 2025.Recent Operational HighlightsElevated Commercial Pool activity with...

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) perspectives on May 19, 2026 at 4:30 pm ET Interim safety and durability data from STARBORN-1 trial of TARA-002 in LMs to be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in May Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Presenting updated 12-month data from Phase 2 ADVANCED-2 trial of TARA-002 in patients with high-grade, BCG-Naïve non-muscle invasive bladder cancer (NMIBC) at the American Urological Association (AUA) Annual...

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) — Swarmer, Inc (“Swarmer” or the “Company”) (Nasdaq: SWMR), a drone autonomy software company which has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today announced financial results for the quarter ended March 31, 2026 (“Q1 2026”), and discussed recent business developments. Management CommentarySwarmer President & U.S. CEO Alex Fink stated: “The first quarter of 2026 represented an important step forward for Swarmer as we completed our initial public offering, strengthened our leadership team and continued to expand our presence within the autonomous systems ecosystem. These milestones support our ability to pursue a rapidly expanding market, as demand for autonomous and collaborative unmanned systems continues to accelerate amid rising deployment...